Aegis Capital Maintains Inovio (INO) at Hold; Still Sees Neutral Risk/Reward Following Q3 Numbers
Tweet Send to a Friend
Aegis Capital affirms its Hold rating and $2.50 price target on Inovio Pharmaceuticals, Inc. (AMEX: INO) following Q3 results issued ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
